As the most common stem cell type being used within regenerative medicine, there is huge potential for growth within the mesenchymal stem cell (MSC) market. Today, MSCs are the most common stem cell type being used within clinical trials, as well as the most studied stem cell type within the scientific literature. [Read more…]
August 22, 2019, Dresden, Germany — Due to their high accessibility and extensive beneficial properties, human Mesenchymal Stem Cells (hMSC) offer exciting promises in a plethora of applications in regenerative medicine, particularly in cell-based therapies. The major challenge of hMSC-based therapy is the large-scale expansion of cells in order to achieve the cell numbers necessary for therapeutic treatment. [Read more…]
In this article, Dr. Daniel Kota provides a mesenchymal stem cell review and explores the future of MSC therapy. Mesenchymal stem cells (MSCs) are multipotent cells that prefer to differentiate into cells of the musculoskeletal system, such as bone, cartilage, muscle and fat cells. However, MSCs can also be induced to become other cell types, as well as exert therapeutic effects by honing to sites of repair and secreting therapeutic agents.
In this article:
I am honored to release this interview with Dr. Ramon Coronado, Executive Director at Lester Smith Medical Research Institute, who started working with exosomes while looking for mechanisms used by MSCs to exert their therapeutic effects. In this interview, we discuss the scientific importance of exosomes, therapeutic and diagnostic applications of exosomes, and their use within encapsulation/delivery systems.
Read on to learn how these extracellular vesicles could transform the future of modern medicine and explore their advantages and disadvantages as compared to cell therapeutics. [Read more…]
What is Cynata’s Cymerus™ Technology?
The Cymerus™ technology is a stem cell manufacturing platform being developed by Cynata Therapeutics Limited (ASX: CYP), an Australian regenerative medicine company. The Cymerus™ technology utilizes induced pluripotent stem cells (iPSCs) originating from an adult donor as the starting material for generating mesenchymoangioblasts (MCAs), and subsequently, for differentiating the cells into mesenchymal stem cells (MSCs). [Read more…]